Join Our Mailing List:
 
Follow Us:
Shop Contact Us
You have 0  Item in Cart | View Cart
310-841-2600
Featured Events
View All Events
Karen Reckamp, M.D., M.S.
Research performed at: City of Hope Comprehensive Cancer Center
Specialty/Research Area: Lung Cancer, Small Cell Lung Cancer
Award Year: 2016, 2015, 2005, 2018

Career Summary: Karen Reckamp, MD, is Associate Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center (COHCCC). She received her medical degree from University of Chicago, and her master’s degree in Clinical Investigation from UCLA. She completed residency training in Internal Medicine at Barnes-Jewish Hospital, and a hematology/Oncology fellowship at the David Geffen School of Medicine at UCLA.

Her research focus is the development of novel therapies for lung cancer with an emphasis on targeted therapies and biomarker assessment. Her activities at City of Hope include Medical Director of the thoracic Oncology program and Chair of the COHCCC scientific review committee. She is a member of the NCCN Lung Cancer, Thymic Malignancies and Mesothelioma Guidelines Committees.  She serves as principal investigator for many Phase I and II studies funded by the NCI, internal funds and industry. Dr. Reckamp is a member of ASCO, AACR, International Association for the Study of Lung Cancer, and SWOG. She participated in the ASCO Leadership Development Program and led the Scientific Committee for metastatic lung cancer for the ASCO annual meeting. Dr. Reckamp has been the past recipient of many honors including Phase I Clinical Investigator Award in 2006 and ASCO/AACR Methods in Clinical Cancer Research Workshop in 2003. She has also authored or co-authored many manuscripts in the field of thoracic Oncology.

Year STOP CANCER Award was received:  2016 Beverly Weiss Memorial Seed Grant, 2015 Beverly Weiss Memorial Seed Grant, 2005 Christina Lopaty Memorial Award

Description of research: Drs. Reckamp and Malkas have assembled an experienced multidisciplinary team to pursue an innovative approach for selectively targeting small cell lung cancer (SCLC). The goal is to better understand the molecular processes that make SCLC sensitive to caPEP, in order to optimize this therapeutic approach. They hypothesize that SCLC, especially SCLC with n-MYC amplification, exhibits significant DNA replication stress, (which results in DNA damage and explains the requirement for PCNA-mediated repair and the susceptibility to caPEP). To test this hypothesis, we propose to evaluate the presence of markers for DNA replication stress in SCLC, and SCLC with n-MYC amplification. Results from these studies will help guide the development of caPEP as a therapeutic intervention for SCLC.

In the Spotlight

STOP CANCER is committed to funding the most promising and innovative scientists in their early research of all forms of cancer prevention, treatment, cures and subsequent clinical applications. STOP CANCER works primarily with local National Cancer Institute-designated Comprehensive Cancer Centers and other qualified institutions in the United States to carry out its mission.

Copyright © 2017 STOP CANCER. All Rights Reserved. | Privacy Policy